Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126201 | 0.96 | HCRTR2 (0.33) | HCRTR2OPRL1ALDH1A1 | |
| SCHEMBL16749128 | 0.85 | L3MBTL1 (0.34) | OPRL1ALDH1A1L3MBTL1PDK2PDK4 | |
| SCHEMBL16749064 | 0.85 | L3MBTL1 (0.37) | OPRL1ALDH1A1L3MBTL1 | |
| SCHEMBL20126321 | 0.82 | GAA (0.36) | ALDH1A1L3MBTL1DPP4 | |
| SCHEMBL20126212 | 0.81 | HTR2C (0.38) | L3MBTL1 | |
| SCHEMBL20126239 | 0.78 | KDM1A (0.32) | ALDH1A1 | |
| SCHEMBL12975731 | 0.77 | HCRTR2 (0.37) | HCRTR2OPRL1DPP4 | |
| SCHEMBL12975802 | 0.77 | HCRTR2 (0.37) | HCRTR2OPRL1DPP4 | |
| SCHEMBL20126345 | 0.77 | OPRL1 (0.38) | OPRL1ALDH1A1L3MBTL1 | |
| SCHEMBL16749143 | 0.76 | OPRL1 (0.42) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | HCRTR2 279/4885OPRL1 313/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.